Researchers from the Tokyo University in collaboration with Shimuzu Corporation and Toppan Printing Company have developed a new blood testing device that can analyze a blood sample and produce results within 80 minutes. The device can also state the exact anthithrombotic requirement for the affected person. Antithrombotic agents, also popularly known as anticoagulants are substances that prevent blood coagulation or clots, and are used to treat medical conditions such as dangerous blood clotting in heart and brain.
Recent studies have shown that anti-clotting therapy reduces the severity of a stroke to a great extent. The study has also shown that the therapy resulted in less severe disability and reduced the death ratio after treatment. Regular intake of anticoagulant drugs such as Warfarin sometimes affects an individual inversely causing heavy nosebleeds and brain hemorrhage. This new device is believed to enable millions of people affected by blood clot to tide the danger without facing any adverse side–effects.
For this study, researchers analyzed two important genes that are directly related to blood clotting and metabolism and found that they are directly linked to the dosage of drugs that can be safely administered. Taking this into account, the researchers developed the testing device, which can estimate the exact amount of anticoagulant drug required by the patient. It can also be used in treating and diagnosing diseases such as leukemia, lung cancer, rheumatism and mental illness. Many hospitals in Japan plan to use this product from April this year.
Syndicate Biopeer
